临床普外科电子杂志 ›› 2023, Vol. 11 ›› Issue (2): 11-.

• • 上一篇    下一篇

利那洛肽治疗功能性便秘致结肠梗阻患者的疗效分析

  

  1. 青岛市第八人民医院 肛肠外科,山东 青岛 266000
  • 出版日期:2023-04-01 发布日期:2023-05-23
  • 基金资助:

    青岛市卫生科技计划资助项目(2020-WJZD100)

Analysis of the efficacy of linaclotide in patients with functional constipation

  1. Anal Surgery Department of Qingdao Eighth People's Hospital, Shandong Qingdao 266100, China
  • Online:2023-04-01 Published:2023-05-23

摘要:

目的 探讨利那洛肽治疗功能性便秘致结肠梗阻患者的疗效。方法 选择2019 年6 月至2022年6 月青岛市第八人民医院诊治的功能性便秘致结肠梗阻患者80 例,采用随机数字表法分为对照组与观察组,各40 例。对照组患者行常规治疗,包括一般治疗、肛管排气、灌肠,观察组在对照组基础上给予利那洛肽治疗。对比两组的疗效、排便次数、粪便性状、腹胀、排便费力感、腹痛评分、便秘特异性生活质量评分,以及两组的不良反应发生情况。结果 观察组的疗效为95.00%,显著高于对照组(77.50%),差异有显著性(P < 0.05)。治疗前,两组患者的粪便性状、排便次数、腹胀、排便费力感、腹痛评分、便秘特异性生活质量评分无显著差异(P > 0.05);治疗后,两组患者的粪便性状、排便次数、明显升高,腹胀、排便费力感、腹痛评分、便秘特异性生活质量评分明显改善,且观察组变化幅度明显较对照组高(P < 0.05)。治疗期间,观察组不良反应发生率为12.50%,对照组为10.00%,无显著差异(P > 0.05)。观察组复发率为2.50%,明显低于对照组(15.00%),差异有显著性(P < 0.05)。结论 利那洛肽可提高功能性便秘患者结肠梗阻的疗效,改善患者的临床症状。

关键词: 利那洛肽, 功能性便秘, 结肠梗阻, 临床症状, 安全性

Abstract:

Objective To explore the efficacy of linaclotide in treating colonic obstruction in patients with functional constipation. Method From June 2019 to June 2022, 80 patients with colonic obstruction caused by functional constipation who were diagnosed and treated by the Eighth People's Hospital of Qingdao City were randomly divided into a control group and an observation group, with 40 patients in each group. The patients in the control group received routine treatment, including general treatment, anal exhaust, and enema. The observation group was treated with linaclotide on the basis of the control group. Compare the efficacy, frequency of defecation, stool characteristics, abdominal distension, sense of difficulty in defecation, abdominal pain scores, constipation

specific quality of life scores, and the occurrence of adverse reactions between the two groups. Result The efficacy of the observation group was 95.00%, significantly higher than that of the control group (77.50%), with a significant difference (P < 0.05). Before treatment, there was no significant difference between the two groups in stool characteristics, defecation frequency, abdominal distension, sense of difficulty in defecation, abdominal pain scores, and constipation specific quality of life scores (P > 0.05); After treatment, the stool characteristics, defecation frequency, and abdominal distension, defecation exertion, abdominal pain scores, and constipation specific quality of life scores of the two groups of patients were significantly increased, and the range of change in the observation group was significantly higher than that in the control group (P < 0.05). During the treatment period, the incidence of adverse reactions was 12.50% in the observation group and 10.00% in the control group, with no significant

difference (P > 0.05). The recurrence rate in the observation group was 2.50%, significantly lower than that in the control group (15.00%), with a significant difference (P < 0.05). Conclusion Linaclotide is effective in improving the clinical outcomes of patients with functional constipation and colonic obstruction.

Key words: Linaclotide, Functional constipation, Colonic obstruction, Clinical symptoms, Safety